Omega Fund Management, LLC Long-Term Concentrated

CIK: 0001637359 · Show all filings

Period: Q4 2025 (← Previous)

Filing Date: Feb 17, 2026

Total Value ($000): $286,520 (100.0% shares, 0.0% debt)

Holdings (11)

Increased Positions (1)

ENGN enGene Holdings Inc. 2.8%

Value ($000) $7,914 (+120.1%) Shares 876,357 (+66.5%) Est. Cost $9.45 Unrealized -15.2%

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
ENGN	enGene Holdings Inc.	876,357 (+66.5%)	$7,914 (+120.1%)	2.8%	$9.45	-15.2%	Common Stock	29286M105

Exited Positions (1)

ENGNW enGene Holdings Inc. 0.0%

Value ($000) $63 Shares 89,702 Est. Cost $0.85 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
ENGNW	enGene Holdings Inc.	89,702	$63	0.0%	$0.85	—	—	29286M113

Decreased Positions (4)

NUVB Nuvation Bio 25.3%

Value ($000) $72,407 (+121.6%) Shares 8,081,089 (-8.5%) Est. Cost $11.18 Unrealized -44.6%

UPB Upstream Bio Inc. 12.6%

Value ($000) $36,009 (+41.1%) Shares 1,326,293 (-2.2%) Est. Cost $22.33 Unrealized +11.5%

KMTS Kestra Med Technologies Ltd 12.7%

Value ($000) $36,428 (-6.8%) Shares 1,373,591 (-16.5%) Est. Cost $22.98 Unrealized +12.1%

BBNX Beta Bionics Inc. 14.0%

Value ($000) $40,104 (+5.1%) Shares 1,316,183 (-31.5%) Est. Cost $18.64 Unrealized +43.2%

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
NUVB	Nuvation Bio	8,081,089 (-8.5%)	$72,407 (+121.6%)	25.3%	$11.18	-44.6%	Common Stock Class A	67080N101
UPB	Upstream Bio Inc.	1,326,293 (-2.2%)	$36,009 (+41.1%)	12.6%	$22.33	+11.5%	Common Stock	91678A107
KMTS	Kestra Med Technologies Ltd	1,373,591 (-16.5%)	$36,428 (-6.8%)	12.7%	$22.98	+12.1%	Common Stock	G52441105
BBNX	Beta Bionics Inc.	1,316,183 (-31.5%)	$40,104 (+5.1%)	14.0%	$18.64	+43.2%	Common Stock	08659B102

Unchanged Positions (6)

ALMS Alumis Inc. 2.2%

Value ($000) $6,375 Shares 653,223 Est. Cost $13.30 Unrealized -47.5%

BBOT BridgeBio Oncology Therapeutics Inc. 14.4%

Value ($000) $41,187 Shares 3,289,661 Est. Cost $11.58 Unrealized —

BCAX Bicara Therapeutics Inc. 12.9%

Value ($000) $37,104 Shares 2,204,650 Est. Cost $25.50 Unrealized -33.0%

REPL Replimune Group 0.8%

Value ($000) $2,417 Shares 248,672 Est. Cost $17.40 Unrealized -51.1%

IMA ImageneBio, Inc. 1.1%

Value ($000) $3,142 Shares 455,361 Est. Cost $13.25 Unrealized -44.1%

SANA Sana Biotechnology, Inc. 1.2%

Value ($000) $3,434 Shares 843,750 Est. Cost $32.56 Unrealized -86.2%

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
ALMS	Alumis Inc.	653,223	$6,375	2.2%	$13.30	-47.5%	Common Stock	022307102
BBOT	BridgeBio Oncology Therapeutics Inc.	3,289,661	$41,187	14.4%	$11.58	—	Common Stock	107924102
BCAX	Bicara Therapeutics Inc.	2,204,650	$37,104	12.9%	$25.50	-33.0%	Common Stock	055477103
REPL	Replimune Group	248,672	$2,417	0.8%	$17.40	-51.1%	Common Stock	76029N106
IMA	ImageneBio, Inc.	455,361	$3,142	1.1%	$13.25	-44.1%	Common Stock	45175G207
SANA	Sana Biotechnology, Inc.	843,750	$3,434	1.2%	$32.56	-86.2%	Common Stock	799566104